Abstract

110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.

Author Details

Authors

• Roy Gerth van Wijk¹
• Ludger Klimek²
• Oliver Pfaar³

Departments

• ¹ Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands,
• ² Center for Rhinology and Allergology, Wiesbaden, and
• ³ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany

Address

Roy Gerth van Wijk, MD, PhD, Professor of Allergy, Section of Allergology and Clinical Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam the Netherlands
Email: [email protected]

Citation